Oligonucleotides

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Last chance to register: Understand LC-MS quantification strategies for proteins

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Learn about LC-MS-based bioanalytical approaches

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Register now to understand advanced LC-MS bioanalytical strategies for biologics

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Monoclonal antibodies
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Quantitative analysis of therapeutic proteins

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

Biologic drugs
#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Explore cutting-edge LC-MS-based bioanalytical approaches

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Webinar: Advanced LC-MS bioanalytical strategies for biologics

A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar, taking place on 27 March, will… Read More

Webinar date:
Supported by Evotec
#News

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Advanced LC-MS bioanalytical strategies for biologics: mAbs, ADCs, and oligonucleotides in complex biological matrices

This event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar will feature a presentation by Dr Marco… Read More

Webinar date:
Supported by Evotec
#Webinars

Avidity Biosciences HQ
#Antibodies #Avidity Biosciences #Bioconjugates #Mergers and acquisitions #Novartis #Oligonucleotides

Novartis acquires Avidity Biosciences for $12 billion

Novartis has entered into a definitive merger agreement with antibody oligonucleotide conjugates (AOCs) developer Avidity Biosciences.   The acquisition will follow the separation of Avidity's early-stage precision cardiology programmes into SpinCo, which is expected to be a publicly traded company.   SpinCo will be led by Kathleen Gallagher, currently Avidity's Chief Program… Read More

#Business & Investment #News

Shalini Andersson
#ELRIG #Events #Oligonucleotides

ELRIG announces keynote speakers for Therapeutic Oligonucleotides

ELRIG has announced that Professor Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, will provide the keynote talks at Therapeutic Oligonucleotides 2025.  The event ‘Therapeutic Oligonucleotides 2025: Drugging the Undruggable’ will take place at AstraZeneca in Gothenburg, Sweden from… Read More

#News

UK on global map
#BioIndustry Association #Oligonucleotides #UK

The UK should lead on oligonucleotides, says BIA

A new report from the BioIndustry Association (BIA) explains the UK’s leadership potential in oligonucleotide therapies.  The report ‘Oligos explainer: A new frontier in precision medicine’ highlights the transformative potential of oligonucleotide therapies.  The precision medicines, which use short DNA… Read More

#News

Transfer RNA
#Alltrna #Flagship Pioneering #Mouse models #Oligonucleotides #Rare disease #RNA #tRNA

First tRNA development candidate restores protein production

Data demonstrate that engineered tRNA from Alltrna’s first development candidate restores protein production to clinically meaningful levels in two disease models driven by the same premature termination codon.  AP003 is a chemically modified, engineered tRNA oligonucleotide in a clinically validated, liver-directed lipid nanoparticle (LNP) that can readthrough… Read More

#News

#CatSci #Innovate UK #Oligonucleotides #Reach Industries #RNA

Innovate UK grant supports development of oligonucleotides

CatSci and Reach Industries have won an Innovate UK grant to accelerate the development of oligonucleotide therapeutics. The grant will fund a collaboration that combines scientific expertise with machine vision tools with an aim to streamline the synthesis, purification and analysis of RNA medicines. Based on the Lumi Visual Intelligence… Read More

#Business & Investment #News

Biochemists working in the lab
#Amyotrophic lateral sclerosis (ALS) #Collaboration #Motor neurone disease #Oligonucleotides #PrecisionLife

R&D partnership to jointly develop new ALS drugs

PrecisionLife and the Nucleic Acid Therapy Accelerator (NATA) have announced a collaboration to co-develop novel oligonucleotide therapies for sporadic motor neurone disease/ALS. The collaboration combines NATA’s expertise in NAT design and optimisation with PrecisionLife’s understanding of complex disease biology and the mechanisms, drug targets and treatments… Read More

#News

GBP pound sterling funding
#CatSci #Funding #Oligonucleotides #RNA sequencing #Wales

CatSci wins Welsh grant for oligonucleotides development

CatSci has won a Welsh Government SMART Capital Equipment Fund grant to enhance its oligonucleotides capability. The grant will enable the company to invest in new equipment that will increase the rapid creation of a large pool of candidates of RNA/DNA sequences. Production of oligonucleotides is currently both slow and… Read More

#Business & Investment #News

Oligonucleotide
#Alpha-1 antitrypsin deficiency #Biopharmaceuticals #Genetic medicines #Korro Bio #Oligonucleotides #RNA

RNA editing oligonucleotide selected for AATD treatment 

Korro Bio, a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110, for the potential treatment of alpha-1 antitrypsin deficiency (AATD).   KRRO-110 is an RNA editing oligonucleotide delivered to liver cells… Read More

#News

Peptide
#CDMO #Manufacturing #Oligonucleotides

Cell-penetrating peptides as a delivery system for oligonucleotides

CDMO in peptides and oligonucleotides manufacturing, Bachem, has started building a new future for oligonucleotides: solving the industry’s main challenges around capacity, sustainability and cost-effectiveness. Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Read More

#Exclusive Content #Opinion